TLGG Consulting, an award-winning management consultancy with a focus on digital strategy, business model innovation and organizational transformation, today released a new white paper: The Future of Clinical Trials is Digital: Are you Ready? The report explains that digital clinical trials (DCTs) are expanding, and are set to improve upon outdated and inefficient processes in traditional clinical research with improved access, retention, analysis and optimization in trial methods, and disrupt the existing medical research ecosystem.
DCTs use novel digital technologies or processes to enable participation outside of conventional clinical settings. The report describes that traditional clinical research processes to develop new medical technologies are plagued by steep costs, lengthy timelines, and high rates of failure, delaying the development of urgently needed new technologies and contributing to increased prices of new products that are successfully developed.
In response to outdated systems, benefits of DCTs include:
Improved Recruitment: Digital tools can open paths to new and more diverse participant subpopulations, improving the equity of medical research.
Increased Retention of Trial Participants: Patient-centric innovations that reduce participant drop-out and lead to quicker trial completion include fewer visits to trial sites, clearer explanations of the trial process, improved communication between researcher and participant, and less burdensome and more automated self-reporting.
Improved Data Collection and Analysis: Digital tools and technologies, including automated monitoring and wearables, lead to more regular, robust, and reliable capture of safety and efficacy data.
Optimized Trial Methods and Designs: Digital tools will enable advanced analysis of trial operations to help determine the most effective methods of participant engagement. DCTs, and their associated cost-savings, could enable product developers to embrace new approaches to research and risk tolerance, and allow them to conduct a wider range of activities in-house.
Katrin Zimmermann, Managing Director of the Americas at TLGG Consulting, said, “The healthcare industry is evolving at an exponential rate and innovative digital technologies and methodologies can improve the development of new drugs, vaccines, and diagnostics. TLGG’s analysis of today’s clinical trial landscape indicates there are great opportunities to increase the speed of research, reduce its cost, and alleviate many of the burdens traditionally associated with participating in a clinical trial. However, the adoption of these trends will have a significant impact on pharma and other research organizations--new business models, skill sets, and team structures will be required to fully leverage the potential of digital trials.”
According to TLGG, the implications of the growing role of DCTs in clinical research are diverse and will impact several stakeholder groups, prompting the need for new business models, new partnerships, new operational processes, and increased prioritization of innovations that focus on improving trial participant experiences. Those impacted will include:
Product Developers: pharmaceutical companies,
Trial Centers: hospitals, universities, and contract research organizations (CROs).
Digital Experts, Service Providers, and Entrepreneurs.
Analysis suggests that current clinical research stakeholders should prepare for an increasingly digital trial ecosystem. In doing so, impacted groups are likely to benefit from guidance relating to digitization and optimization of products, services and systems to improve user experiences.
For more information or to view the full white paper, please visit www.tlggconsulting.com/dct-white-paper/.
TLGG Consulting is a strategy consultancy for the digital age, with a growing team of 50+ digital experts, created in 2018 and spun off from the digital and creative agency TLGG and locations in Berlin and New York. TLGG accompanies organizations and companies through change with a holistic digital approach in all business processes. Their guiding principle is that unique business models require unique solutions. Companies and institutions such as Aurelis, Deutsche Bahn, Lufthansa, Schmitz Cargobull, dena and leading automotive and pharmaceutical companies worldwide rely on the results.
North 6th Agency for TLGG
View source version on newsdirect.com: https://newsdirect.com/news/tlgg-white-paper-reveals-the-future-of-clinical-trials-is-digital-advises-stakeholders-to-prepare-now-366588448